Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...

Biotech stumbled in FY25, but we didn’t. HB Biotechnology kept its footing and delivered 23% outperformance in a tough market ...

In July 2025, global markets have been navigating a complex landscape marked by new U.S. tariff announcements and mixed economic signals, with the Nasdaq Composite Index showing resilience amidst ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

In a recent market update, Goldman Sachs raised its year-end forecast for the S&P 500 (SPX) to 6,900 by year-end, up from a ...

Simulations Plus Inc. reported lower than expected sales and reduced guidance due to cautious biopharma spending.

My all-weather portfolio gained 23% in H1, driven by tech, energy, and real assets amid rate cut hopes. See why I'm targeting ...

These ASX 100 shares could rise in July after a very different past year. Here's what to consider about the two.

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's policies. Health care stocks can often be a solid defensive play in an ...

Thermo Fisher's core pharma, biotech, and bioproduction businesses are driving growth. Click here to read why TMO stock is a ...

IPO stocks like Circle and CoreWeave have highlighted a revived U.S. IPO market. But can the rebound in valuations last?